Mesenchymal stem cells (MSC) is an important type of cell that is highly acclaimed for their safety and efficacy as a therapeutic agent cells. In order to obtain MSC, primary tissue (adipose tissue, bone marrow and cord blood) should be used; However, this network, especially the umbilical cord blood, it is difficult to obtain due to various reasons, such as low birth rate trend. In addition, to maximize the safety and efficacy of the MSC as an allogeneic cell therapy agent, it is desirable to minimize the possibility of immune rejection after transplantation in vivo.

This study attempts to establish a new method for producing induced pluripotent stem cells (IPSC) -derived MSC in which the human leukocyte antigen (HLA) -class I gene knocked out. To do this, derived dermal fibroblasts generation using Yamanaka 4 IPSC-factor, the HLA class I edited IPSC generation using CRISPR / Cas9, and differentiation of the IPSC to the MSC using the MSC culture medium utilized.

Through this, the HLA-A, B, and C pseudo-homozygous IPSC-derived MSCs (KO IMSC) produced by monoallelically knocked out of polymorphic HLA-A, B, and C genes, which are the main cause immune rejection for allogenic cell transplantation , Produced KO Imsc have multipotency and it is safe in vivo can be differentiated into cartilage.

Moreover, not attacked by natural killer cells do not like zero cells of HLA class I. In conclusion, KO Imsc which do not induce immune rejection during transplantation of allogeneic cells can be produced. In the future, KO Imsc can be successfully utilized as a therapeutic agent for multiple recipients of allogeneic cells via HLA typing.

Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells
Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells

human leukocyte antigen matching related donor for patients with sickle cell disease: results of international donors

Sickle cell disease (SCD) is the most common inherited hemoglobinopathies. hematopoietic stem cell transplantation (HCT) is the only curative therapy for SCD, but some patients will have a matched donor siblings. Patients with SCD mostly of African origin, and therefore tend to find a suitable unrelated donors in international registries. Using HaploStats, we estimate HLA haplotypes for 185 patients with SCD (n = 116 from the center of Brazil; n = 69 of the European Society for Blood and Marrow Transplantation (EBMT) centers) and haplotypes classified ethnic origin.

Next, we assess the probability of finding the human leukocyte antigen (HLA) matched unrelated adult donor (MUD), given the locus of A, B and DRB1 (6/6), in the international registries. Most haplotype is Africa, but Brazil showed the ethnic mix of higher than patients EBMT. Nevertheless, the possibility of finding at least one potential donor 6/6 allele was 47% for both groups. Most potential donors alleles derived from the National Marrow Donor Program (NMDP) Registry (USA) and from donor registry Brazil (REDOME).

Although the probability of finding a donor is higher than previously reported, the strategies needed to increase ethnic diversity in applicants. Furthermore, predicting the possibility of having MUD may influence the management of SCD.

Loss of human leukocyte antigen (HLA) class 1 expression is an escape mechanism of tumor immunity and may contribute to resistance to immunotherapy. Patients with lung cancer non-small cell (NSCLC) treated with immune checkpoint inhibitor may have discordant responses between brain metastases and extracranial sites of disease.

We sought to evaluate whether the expression of HLA class 1 is maintained in metastatic NSCLC. NSCLC patients with paired primary and metastatic brain networks identified from the registry of our institution. HLA class 1 expression on the cell membrane of tumor cells is determined by immunohistochemistry.